A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

• Main Authors: Víctor Manuel Navas-López (Author), Gemma Pujol-Muncunill (Author), Enrique Llerena (Author), María Navalón Rubio (Author), David Gil-Ortega (Author), Vicente Varea-Calderón (Author), Carlos Sierra Salinas (Author), Javier Martin- (Author)
• Format: Book
• Published: Elsevier, 2018-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and objectives: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (IFX). In the case series reported, more than 7...